Key result
Gabapentinoid prescribing involved concomitant opioid therapy in almost 40% of patients, and only about half of the usage was for approved indications.
Why the study?
Gabapentinoid prescribing has increased with well-described off-label use that may risk harm, but tertiary care prescribing patterns had not been described in Australia.
What are the prescribing patterns and extent of off-label use of gabapentinoids in a tertiary care setting?
Cross-Sectional
What are the prescribing patterns and extent of off-label use of gabapentinoids in a tertiary care setting?
A significant proportion of gabapentinoid prescribing in tertiary care is for off-label indications and involves concurrent opioid use, highlighting the need for improved prescribing practices.
Answers are grounded in this paper and cite their sources.
May warrant caution with gabapentinoid-opioid co-prescribing; leaves open appropriateness of off-label use in tertiary settings.
Background Prescribing of gabapentinoids has increased worldwide and off‐label use is well‐described. Patients may be at risk of harm from inappropriate use. Prescribing patterns in tertiary care have not been described in the Australian setting. Aim The aim of this study was to assess the prescribing patterns of gabapentinoids across a Local Health District in New South Wales, Australia. Method Clinical and prescribing records over a 48‐h period were reviewed. Patient demographics, renal function and concurrent opioid use were recorded. Dosing details and the indications for treatment were analysed. Results Almost 40% of patients were prescribed concomitant opioid therapy, half of which were in the postoperative setting, an indication for which there is little evidence. Appropriate dose reductions were made in the majority of patients with renal impairment. Methods used for ceasing therapy were not in accordance with best practice. Indications for use were difficult to ascertain from medical records. However, only approximately half of usage of both agents appeared to be for approved indications. Conclusion Prescribing of gabapentinoids could be improved. Although dosages are largely in accordance with recommended dosages for renal impairment, there is significant concern with concurrent use of opioids and use for non‐approved indications, many of which lack clinical evidence. Further investigation into prescribing habits in the postoperative setting is warranted. There is a potential role for increased education and intervention to optimise use.
No takes yet. Share an insight, caveat, or question.
Felicity Prior (2021) conducted a cross-sectional in Gabapentinoid use. Gabapentinoids was evaluated on Prescribing patterns, concurrent opioid use, and indications for treatment. Gabapentinoid prescribing involved concomitant opioid therapy in almost 40% of patients, and only about half of the usage was for approved indications.
Synapse has enriched 10 related papers. Consider them for comparative context: